What's in NuPathe Inc.'s pipeline?

NuPathe Inc. has 3 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with NuPathe Inc.'s portfolio?

Top competitors by shared drug class: Biohaven Therapeutics Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nupathe-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

NuPathe Inc. — Portfolio Competitive Intelligence Brief

NuPathe Inc. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
NP101	NP101	phase 3	5-HT1F receptor agonist	5-HT1F receptor	Neurology
NP101 - Sumatriptan iontophoretic transdermal patch	NP101 - Sumatriptan iontophoretic transdermal patch	phase 3	5-HT1B/1D receptor agonist (triptan)	5-HT1B receptor, 5-HT1D receptor	Neurology

Therapeutic area mix

Neurology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Biohaven Therapeutics Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NuPathe Inc.:

Cite this brief

Drug Landscape (2026). NuPathe Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nupathe-inc. Accessed 2026-05-15.